OccuRx raises awareness of the importance of World Diabetes Day

Melbourne, Australia, 14 November 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, raises awareness of World Diabetes Day (WDD). WDD is the world’s largest diabetes awareness campaign reaching a global audience of over 1 billion people in more than 160 countries. The campaign draws […]

OccuRx team to meet with biotech industry leaders during AusBiotech conference in Perth, Australia

Melbourne, Australia, 20 October 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s AusBiotech Convention will be attended by OccuRx’s Chief Operating Officer, Dr Michelle Bradney. AusBiotech is scheduled to take place 26 – 28 October 2022 in Perth, Western Australia and will […]

OccuRx team to meet with biotech industry leaders during BIO-Europe® conference in Germany

Melbourne, Australia, 17 October 2022: OccuRx,a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. This year’s BIO-Europe Convention will be attended by OccuRx’s Chief Executive Officer, Professor Darren Kelly and Chief Commercial Officer, Dr Gareth Lewis. BIO-Europe® is scheduled to take place 24 – 26 October 2022 […]

OccuRx secures $1.5M to advance its Phase II Chronic Kidney Disease Study

Melbourne, Australia, 20 July 2022: OccuRx has been awarded a $1.5m grant from CUREator, Australia’s biomedical incubator managed by Brandon BioCatalyst. The funds will allow OccuRx to further investigate a novel therapy (OCX063) for treating inflammation and fibrosis in patients with chronic kidney disease (CKD). Chronic kidney disease (including diabetic kidney disease) is one of […]

OccuRx appoints Dr Gareth Lewis as Chief Commercial Officer

Melbourne, Australia, 20 June 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announces Dr Gareth Lewis has been appointed as Chief Commercial Officer. Gareth has over 25 years of R&D experience spanning drug and clinical development, portfolio strategy, pre-launch commercialisation, business development and […]

OccuRx represented at Biotechnology Innovation Organisation (BIO) International Convention in San Diego

Melbourne, Australia, 16 June 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announces its senior team including Executive Chair, Prof Darren Kelly, will be attending the 2022 Biotechnology Innovation Organisation International Convention (“BIO”) held between 13-16 June 2022 in San Diego, California. OccuRx […]

OccuRx appoints Dr Michelle Bradney as Chief Operating Officer

Melbourne, Australia, 15 March 2022: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, today announces Dr Michelle Bradney has been appointed as Chief Operating Officer. Michelle has over 25 years of progressive global clinical development, clinical operations and medical affairs experience working across Australia, Asia […]

Kidney health awareness to be raised during World Kidney Day and Australia’s Kidney Health Week

Melbourne, Australia, 11 March 2021: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases. Today kidney health awareness becomes a focus globally during World Kidney Day. This awareness day precedes Australia’s Kidney Health Week which takes place 15-21 March 2021. OccuRx, is proud to increase global […]